The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics

Drug Metabolism Reviews

Volumn 36, Issue 2, 2004, Pages 313-333

  Miksys, Sharon ^a   Tyndale, Rachel F ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b Department of Pharmacology ^*  (Canada)

Author keywords

Brain; CYP; Cytochromes P450; Drug metabolism; Neurotoxicity

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; COCAINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2A; CYTOCHROME P450 2B1; CYTOCHROME P450 2B6; CYTOCHROME P450 2D1; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DEXTROMETHORPHAN; KETAMINE; MESSENGER RNA; NEUROTOXIN; NICOTINE; PHENCYCLIDINE; PROPOFOL; PROTEIN;

ANIMAL CELL; BLOOD BRAIN BARRIER; BRAIN METABOLISM; BRAIN REGION; CELL SPECIFICITY; CELL TYPE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; GLIA CELL; HUMAN; HUMAN CELL; INDIVIDUALITY; MICROENVIRONMENT; MITOCHONDRIAL MEMBRANE; NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BRAIN; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 3042519581     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-120034149     Document Type: Conference Paper

References (138)

1. Airaksinen, M. M., Kari, I. (1981). Beta-carbolines, psychoactive compounds in the mammalian body. Part I: Occurrence, origin and metabolism. Med. Biol. 59(1):21-34.
2. Anandatheerthavarada, H. K., Shankar, S. K., Ravindranath, V. (1990). Rat brain cytochromes P450: catalytic, immunochemical properties and inducibility of multiple forms. Brain Res. 536:339-343.
3. Anandatheerthavarada, H. K., WIlliams, J. F., Wecker, L. (1993a). The chronic administration of nicotine induces cytochrome P450 in rat brain. J. Neurochem. 60(5):1941-1944.
4. Anandatheerthavarada, H. K., Williams, J. F., Wecker, L. (1993b). Differential effect of chronic nicotine administration on brain cytochrome P4501A1/2 and P4502E1. Biochem. Biophys. Res. Commun. 194(1):312-318.
5. Ariyoshi, N., Miyazaki, M., Toide, K., Sawamura, Y., Kamataki, T. (2001). A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. Biochem. Biophys. Res. Commun. 281(5):1256-1260.
6. Arthur, H., Dahl, M. L., Siwers, B., Sjoqvist, F. (1995). Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J. Clin. Psychopharmacol. 15(3):211-216.
7. Balfour, D. J., Ridley, D. L. (2000). The effects of nicotine on neural pathways implicated in depression: a factor in nicotine addiction? Pharmacol. Biochem. Behav. 66(1):79-85.
8. Batel, P., Pessione, F., Maitre, C., Rueff, B. (1995). Relationship between alcohol and tobacco dependencies among alcoholics who smoke. Addiction 90(7):977-980.
9. Benedetti, M. D., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., Rocca, W. A. (2000). Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 55(9):1350-1358.
10. Benowitz, N. L., Peng, M., Jacob, P. III. (2003). Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin. Pharmacol. Ther. 74(5):468-474.
11. Bhagwat, S. V., Boyd, M. R., Ravindranath, V. (2000). Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria. Biochem. Pharmacol. 59(5):573-582.
12. Bhamre, S., Anandatheerathavarada, H. K., Shankar, S. K. (1993). Purification of multiple forms of cytochrome P450 from a human brain and reconstitution of catalitic activities. Arch. Biochem. Biophys. 301(2):251-255.
13. Blomqvist, O., Ericson, M., Johnson, D. H., Engel, J. A., Soderpalm, B. (1996). Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. Eur. J. Pharmacol. 314(3):257-267.
14. Bordet, R., Broly, F., Destee, A., Libersa, C. (1994). Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson disease and diffuse Lewy body disease. Clin. Neuropharmacol. 17(5):484-488.
15. Boustead, C., Taber, H., Idle, J. R., Cholerton, S. (1997). CYP2D6 genotype and smoking behaviour in cigarette smokers. Pharmacogenetics 7(5):411-414.
16. Chen, Z. R., Irvine, R. J., Bodiner, F., Somogy, A. A. (1990). Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. Life Sci. 46:1067-1074.
17. Chew, M., White, J. M., Somogyi, A. A., Bochner, F., Irvine, R. J. (2001). Precipitated withdrawal following codeine administration is dependent on CYP genotype. Eur. J. Pharmacol. 425(3):159-164.
18. Chinta, S. J., Pai, H. V., Upadhya, S. C., Boyd, M. R., Ravindranath, V. (2002). Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. Brain Res. Mol. Brain Res. 103(1-2):49-61.
19. Chun, J., Kent, U. M., Moss, R. M., Sayre, L. M., Hollenberg, P. F. (2000). Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane. Drug Metab. Dispos. 28(8):905-911.
20. Code, E. L., Crespi, C. L., Penman, B. W., Gonzalez, F. J., Chang, T. K., Waxman, D. J. (1997). Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. 25(8):985-993.
21. Coleman, T., Ellis, S. W., Martin, I. J., Lennard, M. S., Tucker, G. T. (1996). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4-implications for susceptibility to Parkinson's disease. J. Pharmacol. Exp. Ther. 277(2):685-690.
22. Crabb, D. W. (1995). Ethanol oxidizing enzymes: roles in alcohol metabolism and alcoholic liver disease. Prog. Liver Dis. 13:151-172.
23. Dahl, A. R., Hadley, W. M. (1991). Nasal cavity enzymes involved in xenobiotic metabolism: effects on the toxicity of inhalants. Crit. Rev. Toxicol. 21(5):345-372.
24. Ding, X., Kaminsky, L. S. (2003). Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 43:149-173.
25. Ekins, S., Wrighton, S. A. (1999). The role of CYP2B6 in human xenobiotic metabolism. Drug Metab. Rev. 31(3):719-754.
26. Ekins, S., Vandenbranden, M., Ring, B. J., Gillespie, J. S., Yang, T. J., Gelboin, H. V., Wrighton, S. A. (1998). Further characterization of the expression in liver and catalytic activity of CYP2B6. J. Pharmacol. Exp. Ther. 286(3):1253-1259.
27. Fadda, F., Rossetti, Z. L. (1998). Chronic ethanol consumption: from neuroadaptation to neurodegeneration. Prog. Neurobiol. 56(4):385-431.
28. Farin, F. M., Omiecinski, C. J. (1993). Regiospecific expression of cytochrome P-450s and microsomal expoxide hydrolase in human brain tissue. J. Toxicol. Environ. Health 40(2-3):317-335.
29. Fonne-Pfister, R., Bargetzi, M. J., Meyer, U. A. (1987). MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem. Biophys. Res. Commun. 148(3):1144-1150.
30. Fratiglioni, L., Wang, H. X. (2000). Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav. Brain Res. 113(1-2):117-120.
31. Gervot, L., Rochat, B., Gautier, J. C., Bohnenestengel, F., Kroemer, H., Berardinis, V. D., Martin, H., Beaune, P., Waziers, I. D. (1999). Human CYP2B6 expression, inducibility and catalytic activities. Pharmacogenetics 9:295-306.
32. Ghersi-Egea, J. F., Perrin, R., Leininger-Muller, B., Jeandel, M. C. G. C., Floquet, J., Cuny, G., Siest, G., Minn, A. (1993). Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain. Biochem. Pharmacol. 45(3):647-658.
33. Gilham, D. E., Cairns, W., Paine, M. J. I., Modi, S., Poulsom, R., Roberts, G. C. K., Wolf, C. R. (1997). Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 27(1):111-125.
34. Hellmold, H., Rylander, T., Magnusson, M., Reihner, E., Warner, M., Gustafsson, J. A. (1998). Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties. J. Clin. Endocrinol. Metab. 83(3):886-895.
35. Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., Greenblatt, D. J. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. 28(10):1176-1183.
36. Hidestrand, M., Oscarson, M., Salonen, J. S., Nyman, L., Pelkonen, O., Turpeinen, M., Ingelman-Sundberg, M. (2001). CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab. Dispos. 29(11):1480-1484.
37. Hiroi, T., Imaoka, S., Funae, Y. (1998). Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun. 249:838-843.
38. Hiroi, T., Kishimoto, W., Chow, T., Imaoka, S., Igarashi, T., Funae, Y. (2001). Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 142(9):3901-3908.
39. Hoffman, S. M., Nelson, D. R., Keeney, D. S. (2001). Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 11(8):687-698.
40. Howard, L. A., Sellers, E. M., Tyndale, R. F. (2002). The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics 3(2):185-199.
41. Howard, L. A., Ahluwalia, J. S., Lin, S. K., Sellers, E. M., Tyndale, R. F. (2003a). CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. Pharmacogenetics 13(6):321-328.
42. Howard, L. A., Miksys, S., Hoffmann, E., Mash, D., Tyndale, R. F. (2003b). Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br. J. Pharmacol. 138(7):1376-1386.
43. http://www.imm.ki.se/CYPalleles/cyp2b6.htm (accessed December 2003).
44. http://www.imm.ki.se/CYPalleles/cyp2d6.htm (accessed December 2003).
45. http://www.imm.ki.se/CYPalleles/cyp2e1.htm (accessed December 2003).
46. Huang, Z., Roy, P., Waxman, D. J. (2000). Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. 59(8):961-972.
47. Hukkanen, J., Pelkonen, O., Hakkola, J., Raunio, H. (2002). Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit. Rev. Toxicol. 32(5):391-411.
48. Ingelman-Sundberg, M. (2002). Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 181-182:447-452.
49. Jacob, P. III, Ulgen, M., Gorrod, J. W. (1997). Metabolism of (-)-(S)-nicotine by guinea pig and rat brain: identification of cotinine. Eur. J. Drug Metab. Pharmacokitet. 22(4):391-394.
50. Janmohamed, A., Dolphin, C. T., Phillips, I. R., Shephard, E. A. (2001). Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. Biochem. Pharmacol. 62(6):777-786.
51. Jinno, H., Tanaka-Kagawa, T., Ohno, A., Makino, Y., Matsushima, E., Hanioka, N., Ando, M. (2003). Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos. 31(4):398-403.
52. Jolivalt, C., Minn, A., Vincent-Viry, M., Galteau, M. -M., Siest, G. (1995). Dextromethorphan O-demethylase activity in rat brain microsomes. Neurosci. Lett. 187:65-68.
53. Kathiramalainathan, K., Kaplan, H. L., Romach, M. K., Busto, U. E., Li, N. Y., Sawe, J., Tyndale, R. F., Sellers, E. M. (2000). Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. J. Clin. Psychopharmacol. 20(4):435-444.
54. Kempermann, G., Knoth, R., Gebicke-Haerter, P. J., Stolz, B. J., Volk, B. (1994). Cytochrome P450 in rat astrocytes in vivo and in vitro: intracellular localization and induction by phenytoin. J. Neurosci. Res. 39(5):576-588.
55. Kirchheiner, J., Klein, C., Meineke, I., Sasse, J., Zanger, U. M., Murdter, T. E., Roots, I., Brockmoller, J. (2003). Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13(10):619-626.
56. Kishimoto, W., Hiroi, T., Shiraishi, M., Osada, M., Imaoka, S., Kominami, S., Igarashi, T., Funai, Y. (2004). Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology 145(2):699-705.
57. Kopun, M., Propping, P. (1977). The kinetics of ethanol absorption and elimination in twins and supplementary repetitive experiments in singleton subjects. Eur. J. Clin. Pharmacol. 11(5):337-344.
58. Kreth, K., Kovar, K., Schwab, M., Zanger, U. M. (2000). Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem. Pharmacol. 59(12):1563-1571.
59. Kumagai, Y., Lin, L. Y., Hiratsuka, A., Narimatsu, S., Suzuki, T., Yamada, H., Oguri, K., Yoshimura, H., Cho, A. K. (1994). Participation of cytochrome P450-2B and -2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats. Mol. Pharmacol. 45(2):359-365.
60. Kurth, M. C., Kurth, J. H. (1993). Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am. J. Med. Genet. 48(3):166-168.
61. Lamba, V., Lamba, J., Yasuda, K., Strom, S., Davila, J., Hancock, M. L., Fackenthal, J. D., Rogan, P. K., Ring, B., Wrighton, S. A., Schuetz, E. G. (2003). Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. 307(3):906-922.
62. Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M., Zanger, U. M. (2001). Extensive genetic polymophism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
63. Lee, M., Wrensch, M., Miike, R. (1997). Dietary and tobacco risk factors for adult onset glioma in the San Francisco Bay Area (California, USA). Cancer Causes Control 8(1):13-24.
64. Lieber, C. S. (1997). Cytochrome P-4502E1: its physiological and pathological role. Physiol. Rev. 77(2):517-544.
65. Lieber, C. S. (1999). Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998) - a review. Alcohol., Clin. Exp. Res. 23(6):991-1007.
66. Lin, L. Y., Kumagai, Y., Cho, A. K. (1992). Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy) methamphetamine by rat brain microsomes. Chem. Res. Toxicol. 5:401-406.
67. Llerena, A., Edman, G., Cobaleda, J., Benitez, J., Schalling, D., Bertilsson, L. (1993). Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 87(1):23-28.
68. Llerena, A., Cobaleda, J., Martinez, C., Benitez, J. (1996). Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur. J. Drug Metab. Pharmacokinet. 21(2):129-138.
69. Loeper, J., Descatoire, V., Maurice, M., Beaune, P., Belghiti, J., Houssin, D., Ballet, F., Feldmann, G., Guengerich, F. P., Pessayre, D. (1993). Cytochromes P-450 in human hepatocyte plasma membrane: recognition by several autoantibodies. Gastroenterology 104(1):203-216.
70. Lundqvist, C., Alling, C., Knoth, R., Volk, B. (1995). Intermittent ethanol exposure of adult rats: hippocampal cell loss after one month of treatment. Alcohol Alcohol. 30(6):737-748.
71. McFadyen, M. C. E., Melvin, W. T., Murray, G. I. (1998). Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem. Pharmacol. 55:825-830.
72. Melchior, C., Collins, M. A. (1982). The route and significance of endogenous synthesis of alkaloids in animals. Crit. Rev. Toxicol. 9(4):313-356.
73. Messina, E. S., Tyndale, R. F., Sellers, E. M. (1997). A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 282(3):1608-1614.
74. Meyer, U. A., Skoda, R. C., Zanger, U. M. (1990). The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. Pharmacol. Ther. 46:297-308.
75. Miksys, S. L., Tyndale, R. F. (2002). Drug-metabolizing cytochrome P450s in the brain. J. Psychiatry Neurosci. 27(6):406-415.
76. Miksys, S., Rao, Y., M. Sellers, E., Kwan, M., Mendis, D., F. Tyndale, R. (2000a). Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica 30(6):547-564.
77. Miksys, S., Hoffmann, E., Tyndale, R. F. (2000b). Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem. Pharmacol. 59:1501-1511.
78. Miksys, S., Rao, Y., Hoffmann, E., Mash, D. C., Tyndale, R. F. (2002). Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J. Neurochem. 82(6):1376-1387.
79. Miksys, S., Lerman, C., Shields, P. G., Mash, D. C., Tyndale, R. F. (2003). Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45(1):122-132.
80. Miller, G. P., Hanna, I. H., Nishimura, Y., Guengerich, F. P. (2001). Oxidation of phenethylamine derivatives by cytochrome P450 2D6: the issue of substrate protonation in binding and catalysis. Biochemistry 40(47):14215-14223.
81. Montoliu, C., Valles, S., Renau-Piqueras, J., Guerri, C. (1994). Ethanol-induced oxygen radical formation and lipid peroxidation in rat brain: effect of chronic alcohol consumption. J. Neurochem. 63(5):1855-1862.
82. Montoliu, C., Sancho-Tello, M., Azorin, I., Burgal, M., Valles, S., Renau-Piqueras, J., Guerri, C. (1995). Ethanol increases cytochrome P4502E1 and induces oxidative stress in astrocytes. J. Neurochem. 65(6):2561-2570.
83. Muskhelishvili, L., Thompson, P. A., Kusewitt, D. F., Wang, C., Kadlubar, F. F. (2001). In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J. Histochem. Cytochem. 49(2):229-236.
84. Mutch, E., Blain, P. G., Williams, F. M. (1999). The role of metabolism in determining susceptibility to parathion toxicity in man. Toxicol. Lett. 107(1-3):177-187.
85. Nakayama, H., Okuda, H., Nakashima, T., Imaoka, S., Funae, Y. (1993). Nicotine metabolism by rat hepatic cytochrome P450s. Biochem. Pharmacol. 45(12):2554-2556.
86. Neve, E. P.A., Eliasson, E., Pronzato, M. A., Albano, E., Marinari, U., Ingelman-Sundberg, M. (1996). Enzyme-specific transport of rat liver cytochrome P450 to the Golgi apparatus. Arch. Biochem. Biophys. 333(2):459-465.
87. Nissbrandt, H., Bergquist, F., Jonason, J., Engberg, F. (2001). Inhibition of cytochrome P450 2E1 induces an increase in extracellular dopamine in rat substanti nigra: a new metabolic pathway? Synapse 40:294-301.
88. Norris, P. J., Hardwick, J. P., Emson, P. C. (1996). Regional distribution of cytochrome P450 2D1 in the rat central nervous system. J. Comp. Neurol. 366:244-258.
89. Oda, Y., Hamaoka, N., Hiroi, T., Imaoka, S., Hase, I., Tanaka, K., Funae, Y., Ishizaki, T., Asada, A. (2001). Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br. J. Clin. Pharmacol. 51(3):281-285.
90. Ohe, T., Hirobe, M., Mashino, T. (2000). Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab. Dispos. 28(2):110-112.
91. Ohmori, O., Suzuki, T., Kojima, H., Shinkai, T., Terao, T., Mita, T., Abe, K. (1998). Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr. Res. 32(2):107-113.
92. Parkinson, A. (2001). Biotransformation of xenobiotics. In: Klasson, C. D., ed. Casarett and Doull's Toxicology; The Basic Science of Poisons. 6th ed. New York: The McGraw-Hill Companies, pp. 133-224.
93. Pasanen, M., Pelkonen, O. (1994). The expression and environmental regulation of P450 enzymes in human placenta. Crit. Rev. Toxicol. 24(3):211-229.
94. Pascussi, J. M., Gerbal-Chaloin, S., Drocourt, L., Maurel, P., Vilarem, M. J. (2003). The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta 1619(3):243-253.
95. Pellinen, P., Kulmala, L., Konttila, J., Auriola, S., Pasanen, M., Juvonen, R. (2000). Kinetic characteristics of norcocaine N-hydroxylation in mouse and human liver microsomes: involvement of CYP enzymes. Arch. Toxicol. 74(9):511-520.
96. Poirier, M. F., Canceil, O., Bayle, F., Millet, B., Bourdel, M. C., Moatti, C., Olie, J. P., Attar-Levy, D. (2002). Prevalence of smoking in psychiatric patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 26(3):529-537.
97. Richmond, R., Zwar, N. (2003). Review of bupropion for smoking cessation. Drug Alochol Rev. 22(2):203-220.
98. Riedl, A. G., Watts, P. M., Jenner, P., Marsden, C. D. (1998). P450 enzymes and Parkinson's disease: the story so far. Mov. Disord. 13(2):212-220.
99. Riley, J. N., Walker, D. W. (1978). Morphological alterations in hippocampus after long-term alcohol consumption in mice. Science 201(4356):646-648.
100. Rosenbrock, H., Hagemeyer, C. E., Singec, I., Knoth, R., Volk, B. (1999). Testosterone metabolism in rat brain is differentially enhanced by phentoin-inducible cytochrome P450 isoforms. J. Neuroendocrinol. 11(8):597-604.
101. Rosenbrock, H., Hagemeyer, C. E., Ditter, M., Knoth, R., Volk, B. (2001). Expression and localization of the CYP2B subfamily predominantly in neurones of rat brain. J. Neurochem. 76:332-340.
102. Roy, A., DeJong, J., Lamparski, D., George, T., Linnoila, M. (1991). Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables. Arch. Gen. Psychiatry 48(5):428-432.
103. Saarikoski, S. T., Sata, F., Husgafvel-Pursiainen, K., Rautalahti, M., Haukka, J., Impivaara, O., Jarvisalo, J., Vainio, H., Hirvonen, A. (2000). CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. Pharmacogenetics 10(1):5-10.
104. Saitoh, T., Xia, Y., Chen, X., Masliah, E., Galasko, D., Shults, C., Thal, L. J., Hansen, L. A., Katzman, R. (1995). The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann. Neurol. 37(1):110-112.
105. Salonen, J. S., Nyman, L., Boobis, A. R., Edwards, R. J., Watts, P., Lake, B. G., Price, R. J., Renwick, A. B., Gomez-Lechon, M. J., Castell, J. V., Ingelman-Sundberg, M., Hidestrand, M., Guillouzo, A., Corcos, L., Goldfarb, P. S., Lewis, D. F., Taavitsainen, P., Pelkonen, O. (2003). Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab. Dispos. 31(9):1093-1102.
106. Schilter, B., Anderson, M. R., Acharya, C., Omiecinski, C. J. (2000). Activation of cytochrome P450 gene expression in the rat brain by phenobarbital-like inducers. J. Pharmacol. Exp. Ther. 294:916-922.
107. Schoedel, K. A., Sellers, E. M., Tyndale, R. F. (2001). Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochem. Pharmacol. 62(8):1025-1036.
108. Schoedel, K. A., Tyndale, R. F. (2003). Induction of nicotine- metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. Biochim. Biophys. Acta 1619(3):283-290.
109. Schoedel, K. A., Sellers, E. M., Palmour, R., Tyndale, R. F. (2003). Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol. Pharmacol. 63(1):96-104.
110. Siegle, I., Fritz, P., Eckhardt, K., Zanger, U. M., Eichelbaum, M. (2001). Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11:237-245.
111. Sohda, T., Shimizu, M., Kamimura, S., Okumura, M. (1993). Immunohistochemical demonstration of ethanol-inducible P450 2E1 in rat brain. Alcohol Alcohol. 28:69-75.
112. Strobel, H. W., Thompson, C. M., Antonovic, L. (2001). Cytochrome P450 in brain: function and significance. Curr. Drug Metab. 2(2):199-214.
113. Tanaka, S., Chen, X., Xia, Y., Kang, D. E., Matoh, N., Sundsmo, M., Thomas, R. G., Katzman, R., Thal, L. J., Trojanowski, J. Q., Saitoh, T., Ueda, K., Masliah, E. (1998). Association of CYP2D microsatellite polymorphism with Lewy body variant of Alzheimer's disease. Neurology 50(6):1556-1562.
114. Tindberg, N., Ingelman-Sundberg, M. (1996). Expression, catalytic activity, and inducibility of cytochrome P450 2E1 (CYP2E1) in the rat central nervous system. J. Neurochem. 67(5):2066-2073.
115. Torvik, A., Torp, S. (1986). The prevalence of alcoholic cerebellar atrophy. A morphometric and histological study of an autopsy material. J. Neurol. Sci. 75(1):43-51.
116. Tredaniel, J., Boffetta, P., Saracci, R., Hirsch, A. (1993). Environmental tobacco smoke and the risk of cancer in adults. Eur. J. Cancer 14:2058-2068.
117. Tyndale, R. F. (2003). Genetics of alcohol and tobacco use in humans. Ann. Med. 35(2):94-121.
118. Tyndale, R. F., Sunahara, R., Inaba, T., Kalow, W., Gonzalez, F. J., Niznik, H. B. (1991). Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type) : potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol. Pharmacol. 40:63-68.
119. Tyndale, R. F., Li, Y., Li, N. -Y., Messina, E., Miksys, S., Sellers, E. M. (1999). Characterization of cytochrome P-450 2D1 activity in rat brain; high-affinity kinetics for dextromethorphan. Drug Metab. Dispos. 27(8):924-930.
120. Upadhya, S. C., Tirumalai, P. S., Boyd, M. R., Mori, T., Ravindranath, V. (2000). Cytochrome P4502E (CYP2E) in brain: constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization. Arch. Biochem. Biophys. 373(1):23-34.
121. Villard, P. H., Seree, E. M., Re, J. L., De Meo, M., Barra, Y., Attolini, L., Dumenil, G., Catalin, J., Durand, A., Lacarelle, B. (1998). Effects of tobacco smoke on the gene expression of the Cyp1a, Cyp2b, Cyp2e, and Cyp3a subfamilies in mouse liver and lung: relation to single strand breaks of DNA. Toxicol. Appl. Pharmacol. 148(2):195-204.
122. Vincent-Viry, M., Fournier, B., Galteau, M.-M. (2000). The effects of drinking and smoking on the CYP2D6 metabolic capacity. Drug Metab. Dispos. 28:617-619.
123. Volk, B., Meyer, R. P., Lintig, F. v., Ibach, B., Knoth, R. (1995). Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin- and phenobarbital-inducible forms. Toxicol. Lett. 82/83:(655-622).
124. Wadelius, M., Darj, E., Frenne, G., Rane, A. (1997). Induction of CYP2D6 in pregnancy. Clin. Pharmacol. Ther. 62(4):400-407.
125. Warner, M., Gustafsson, J. A. (1994). Effect of ethanol on cytochrome P450 in the rat brain. Proc. Natl. Acad. Sci. U. S. A. 91(3):1019-1023.
126. Warner, M., Hellmold, H., Yoshida, S., Liao, D., Hedlund, E., Gustafsson, J. A. (1997). Cytochrome P450 in the breast and brain: role in tissue-specific activation of xenobiotics. Mutat. Res. 376(1-2):79-85.
127. Woodcroft, K. J., Novak, R. F. (1998). Xenobiotic-enhanced expression of cytochromes P450 2E1 and 2B in primary cultured rat hepatocytes. Drug Metab. Dispos. 26(4):372-378.
128. Wu, D., Cederbaum, A. I. (1992). Presence of functionally active cytochrome P-450IIEI in the plasma membrane of rat hepatocytes. Hepatology 15(3):515-524.
129. Yamazaki, H., Inoue, K., Hashimoto, M., Shimada, T. (1999). Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch. Toxicol. 73(2):65-70.
130. Yanagihara, Y., Kariya, S., Ohtani, M., Uchino, K., Aoyama, T., Yamamura, Y., Iga, T. (2001). Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metab. Dispos. 29(6):887-890.
131. Yengi, L. G., Xiang, Q., Pan, J., Scatina, J., Kao, J., Ball, S. E., Fruncillo, R., Ferron, G., Roland Wolf, C. (2003). Quantitation of cytochrome P450 mRNA levels in human skin. Anal. Biochem. 316(1):103-110.
132. Yu, A. M., Idle, J. R., Herraiz, T., Kupfer, A., Gonzalez, F. J. (2003a). Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13(6):307-319.
133. Yu, A. M., Idle, J. R., Byrd, L. G., Krausz, K. W., Kupfer, A., Gonzalez, F. J. (2003b). Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13(3):173-181.
134. Yu, A. M., Idle, J. R., Krausz, K. W., Kupfer, A., Gonzalez, F. J. (2003c). Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J. Pharmacol. Exp. Ther. 305(1):315-322.
135. Zanger, U. M., Raimundo, S., Eichelbaum, M. (2004). Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Arch. Pharmacol. 369(1):23-37.
136. Zhang, Y., Benet, L. Z. (2001). The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 40(3):159-168.
137. Zhukov, A., Ingelman-Sundberg, M. (1999). Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of ethanol-inducible cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron donor NADPH-cytochrome P450 reductase. Biochem. J. 340(Pt. 2):453-458.
138. Zimatkin, S. M., Liopo, A. V., Deitrich, R. A. (1998). Distribution and kinetics of ethanol metabolism in rat brain. Alcohol., Clin. Exp. Res. 22(8):1623-1627.